SlideShare a Scribd company logo

ALETA CNS metastasis program 8 July 2020

Slide deck used for video presentation to the OCTS conference. Her2-positive CNS metastases plague refractory breast cancer patients. Here we present our wholly novel approach to cell therapy for the treatment of these patients. #celltherapy #oncology #breastcancer

1 of 28
Download to read offline
A Novel Platform for Cell Therapeutics
Our Journey from Bench to Clinical Development
8 July 2020
Paul D Rennert, President & CSO, Aleta Biotherapeutics
CAR T cells work because
they bind tumor antigens
Cytotoxicity: This encounter triggers the CAR
T cell to secrete factors that kill the tumor cells
Serial killing: Each CAR T cell can find and
kill up to 1000 tumor cells
Proliferation: During that time the CAR T cell
reproduces again and again, creating clones
of itself that can carry on the anti-tumor
activity
Persistence: The target tumor protein must
be consistently expressed at a high enough
level to support CAR T cell expansion and
persistence in the patient
OCTS July 7-9, 20202
When they work, cell therapies
produce amazing and curative
benefit in relapsed patients with
no other recourse
Approved anti-CD19 CAR T cell
therapies for refractory B cell leukemia
and lymphomas
Emily Whitehead, 8 years after treatment with Kymriah,
with no trace of leukemia, and still carrying her CAR T cells
OCTS July 7-9, 20203
OCTS July 7-9, 20204
CAR-T cells that target CD19 have
exemplary characteristics
• CAR-T cell persistence is a natural attribute of anti-CD19 CAR T cells because
they can expand and persist using normal CD19+ B cells
‣ Normal B cells are a non-tumor dependent, self-renewing antigen source
‣ This antigen depot allows the CAR T cells to outlast and outlive the tumor cells
• CAR-T cell fitness is naturally enhanced by the interaction with normal B cells
• anti-CD19 CAR T cells are known to traffic throughout the patient, including
into the central nervous system
Persistence, fitness, trafficking
Other CAR T cells just don’t work as well:
why not?
OCTS July 7-9, 20205
Critical issues confront CAR T cell
therapeutics for solid tumors
• CAR T Cell Persistence is often poor in solid tumor indications
• CAR T Cell Fitness can be limited by exhaustion and immunosuppression
• CAR T Cell Trafficking may limit access to the tumor
• Antigen Escape thwarts therapy due to the loss of tumor antigen expression
• Patient Safety can be compromised when CAR T cells attack critical normal cells
and tissues
6 OCTS July 7-9, 2020

Recommended

More Related Content

Similar to ALETA CNS metastasis program 8 July 2020

Advances-in-car-t-cell-therapy-research.pdf
Advances-in-car-t-cell-therapy-research.pdfAdvances-in-car-t-cell-therapy-research.pdf
Advances-in-car-t-cell-therapy-research.pdfssuser54a9d9
 
CAR-T Cell Therapy slide share
CAR-T Cell Therapy slide shareCAR-T Cell Therapy slide share
CAR-T Cell Therapy slide shareMSKhanvideochannel
 
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsChimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsCreative-Biolabs
 
CAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORSCAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORSClaire Roudot
 
Cart cell in rheumatology ppt.pdf
Cart cell in rheumatology ppt.pdfCart cell in rheumatology ppt.pdf
Cart cell in rheumatology ppt.pdfGautamPanjabi1
 
Car t cell basics cell therapy working group 11.21.19
Car t cell basics  cell therapy working group 11.21.19Car t cell basics  cell therapy working group 11.21.19
Car t cell basics cell therapy working group 11.21.19Miomir Knežević
 
CAR T cell basics -cell therapy working group 11.21.19.pptx
CAR T cell basics -cell therapy working group 11.21.19.pptxCAR T cell basics -cell therapy working group 11.21.19.pptx
CAR T cell basics -cell therapy working group 11.21.19.pptxMuhammad Naeem
 
Engineering cd19 specific t lymphocytes with interleukin-15 and a suicide gen...
Engineering cd19 specific t lymphocytes with interleukin-15 and a suicide gen...Engineering cd19 specific t lymphocytes with interleukin-15 and a suicide gen...
Engineering cd19 specific t lymphocytes with interleukin-15 and a suicide gen...qussai abbas
 
Dendritic Vaccines Glioma 2016
Dendritic Vaccines Glioma 2016Dendritic Vaccines Glioma 2016
Dendritic Vaccines Glioma 2016NeuroAcademy
 
Io combos and the big stick
Io combos and the big stick Io combos and the big stick
Io combos and the big stick Paul D. Rennert
 
Immunotherapy beyond checkpoints inhibitors
Immunotherapy beyond checkpoints inhibitorsImmunotherapy beyond checkpoints inhibitors
Immunotherapy beyond checkpoints inhibitorsGaurav Kumar
 
Andre Radensky Sigma Xi
Andre Radensky Sigma XiAndre Radensky Sigma Xi
Andre Radensky Sigma Xiaradensky
 
CAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya OzawaCAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya Ozawaspa718
 
CAR-T cell immunotherapy for solid tumors
CAR-T cell immunotherapy for solid tumorsCAR-T cell immunotherapy for solid tumors
CAR-T cell immunotherapy for solid tumorsSushma Ahirwar
 
Rennert et al. ASH 2019 talk
Rennert et al. ASH 2019 talkRennert et al. ASH 2019 talk
Rennert et al. ASH 2019 talkPaul D. Rennert
 
Chapter 17 immunotherapy
Chapter 17 immunotherapyChapter 17 immunotherapy
Chapter 17 immunotherapyNilesh Kucha
 
Humanisation of antibodies & immunotherapeutics in clinical practice
Humanisation of antibodies  & immunotherapeutics in clinical practice Humanisation of antibodies  & immunotherapeutics in clinical practice
Humanisation of antibodies & immunotherapeutics in clinical practice Aaqib Naseer
 

Similar to ALETA CNS metastasis program 8 July 2020 (20)

Advances-in-car-t-cell-therapy-research.pdf
Advances-in-car-t-cell-therapy-research.pdfAdvances-in-car-t-cell-therapy-research.pdf
Advances-in-car-t-cell-therapy-research.pdf
 
CAR-T Cell Therapy slide share
CAR-T Cell Therapy slide shareCAR-T Cell Therapy slide share
CAR-T Cell Therapy slide share
 
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsChimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
 
CAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORSCAR-T CELLS IN SOLID TUMORS
CAR-T CELLS IN SOLID TUMORS
 
Cart cell in rheumatology ppt.pdf
Cart cell in rheumatology ppt.pdfCart cell in rheumatology ppt.pdf
Cart cell in rheumatology ppt.pdf
 
Car t cell basics cell therapy working group 11.21.19
Car t cell basics  cell therapy working group 11.21.19Car t cell basics  cell therapy working group 11.21.19
Car t cell basics cell therapy working group 11.21.19
 
CAR T cell basics -cell therapy working group 11.21.19.pptx
CAR T cell basics -cell therapy working group 11.21.19.pptxCAR T cell basics -cell therapy working group 11.21.19.pptx
CAR T cell basics -cell therapy working group 11.21.19.pptx
 
Immune cell therapy
Immune cell therapyImmune cell therapy
Immune cell therapy
 
New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...
New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...
New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine a...
 
Engineering cd19 specific t lymphocytes with interleukin-15 and a suicide gen...
Engineering cd19 specific t lymphocytes with interleukin-15 and a suicide gen...Engineering cd19 specific t lymphocytes with interleukin-15 and a suicide gen...
Engineering cd19 specific t lymphocytes with interleukin-15 and a suicide gen...
 
Car tcell therapy
Car tcell therapyCar tcell therapy
Car tcell therapy
 
Dendritic Vaccines Glioma 2016
Dendritic Vaccines Glioma 2016Dendritic Vaccines Glioma 2016
Dendritic Vaccines Glioma 2016
 
Io combos and the big stick
Io combos and the big stick Io combos and the big stick
Io combos and the big stick
 
Immunotherapy beyond checkpoints inhibitors
Immunotherapy beyond checkpoints inhibitorsImmunotherapy beyond checkpoints inhibitors
Immunotherapy beyond checkpoints inhibitors
 
Andre Radensky Sigma Xi
Andre Radensky Sigma XiAndre Radensky Sigma Xi
Andre Radensky Sigma Xi
 
CAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya OzawaCAR-T cells in Leukemia. Prof. Keiya Ozawa
CAR-T cells in Leukemia. Prof. Keiya Ozawa
 
CAR-T cell immunotherapy for solid tumors
CAR-T cell immunotherapy for solid tumorsCAR-T cell immunotherapy for solid tumors
CAR-T cell immunotherapy for solid tumors
 
Rennert et al. ASH 2019 talk
Rennert et al. ASH 2019 talkRennert et al. ASH 2019 talk
Rennert et al. ASH 2019 talk
 
Chapter 17 immunotherapy
Chapter 17 immunotherapyChapter 17 immunotherapy
Chapter 17 immunotherapy
 
Humanisation of antibodies & immunotherapeutics in clinical practice
Humanisation of antibodies  & immunotherapeutics in clinical practice Humanisation of antibodies  & immunotherapeutics in clinical practice
Humanisation of antibodies & immunotherapeutics in clinical practice
 

Recently uploaded

Seminario biologia molecular-Universidad Pontificia Bolivariana.
Seminario biologia molecular-Universidad Pontificia Bolivariana.Seminario biologia molecular-Universidad Pontificia Bolivariana.
Seminario biologia molecular-Universidad Pontificia Bolivariana.JULIANA BENAVIDES GUERRERO
 
Ascariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Ascariasis.pptx Department of Physiotherapy, SHUATS, PrayagrajAscariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Ascariasis.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...Abhinav S
 
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.vrchk912
 
1030am-CLEAR-OUTCOMES-acc-2023- Bemp.pdf
1030am-CLEAR-OUTCOMES-acc-2023- Bemp.pdf1030am-CLEAR-OUTCOMES-acc-2023- Bemp.pdf
1030am-CLEAR-OUTCOMES-acc-2023- Bemp.pdfthomasbetancourtmd
 
Impact of Early Pregnancy---Lecture-2024
Impact of Early Pregnancy---Lecture-2024Impact of Early Pregnancy---Lecture-2024
Impact of Early Pregnancy---Lecture-2024ERWINPEJI2
 
Best neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab IndiaBest neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab IndiaNHS Hospital
 
PTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxPTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxvideosfildr
 
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajPoliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Health powerpoint for catch -up fridays.
Health powerpoint for catch -up fridays.Health powerpoint for catch -up fridays.
Health powerpoint for catch -up fridays.JohnMarckySeoTeriomp
 
A complete guide to the Human Digestive System
A complete guide to the Human Digestive SystemA complete guide to the Human Digestive System
A complete guide to the Human Digestive Systemantoneymichael992
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Golden Helix
 
Population of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxPopulation of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxDr. Dheeraj Kumar
 
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajMeasles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxArtificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxDr. Dheeraj Kumar
 
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...Dr. Madduru Muni Haritha
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSPAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSDr.Shrikrushna Sobaji
 
Introducing amazing Healthy habits and fitness
Introducing amazing Healthy habits and fitnessIntroducing amazing Healthy habits and fitness
Introducing amazing Healthy habits and fitnessFredrick Amos
 
Seminario Biología Molecular Manuela Álvarez Ramírez
Seminario Biología Molecular Manuela Álvarez RamírezSeminario Biología Molecular Manuela Álvarez Ramírez
Seminario Biología Molecular Manuela Álvarez Ramírezmanuelaalvarezr
 

Recently uploaded (20)

Seminario biologia molecular-Universidad Pontificia Bolivariana.
Seminario biologia molecular-Universidad Pontificia Bolivariana.Seminario biologia molecular-Universidad Pontificia Bolivariana.
Seminario biologia molecular-Universidad Pontificia Bolivariana.
 
Ascariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Ascariasis.pptx Department of Physiotherapy, SHUATS, PrayagrajAscariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Ascariasis.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
 
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
 
1030am-CLEAR-OUTCOMES-acc-2023- Bemp.pdf
1030am-CLEAR-OUTCOMES-acc-2023- Bemp.pdf1030am-CLEAR-OUTCOMES-acc-2023- Bemp.pdf
1030am-CLEAR-OUTCOMES-acc-2023- Bemp.pdf
 
Impact of Early Pregnancy---Lecture-2024
Impact of Early Pregnancy---Lecture-2024Impact of Early Pregnancy---Lecture-2024
Impact of Early Pregnancy---Lecture-2024
 
Best neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab IndiaBest neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab India
 
PTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxPTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptx
 
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajPoliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Health powerpoint for catch -up fridays.
Health powerpoint for catch -up fridays.Health powerpoint for catch -up fridays.
Health powerpoint for catch -up fridays.
 
A complete guide to the Human Digestive System
A complete guide to the Human Digestive SystemA complete guide to the Human Digestive System
A complete guide to the Human Digestive System
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
 
Population of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxPopulation of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptx
 
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajMeasles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxArtificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
 
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
SCIENTIFIC APPROACH OF DIET IN MASANUMASIKA GARBINI PARICHARYA – FOR A HEALTH...
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
 
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSPAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
 
Introducing amazing Healthy habits and fitness
Introducing amazing Healthy habits and fitnessIntroducing amazing Healthy habits and fitness
Introducing amazing Healthy habits and fitness
 
Seminario Biología Molecular Manuela Álvarez Ramírez
Seminario Biología Molecular Manuela Álvarez RamírezSeminario Biología Molecular Manuela Álvarez Ramírez
Seminario Biología Molecular Manuela Álvarez Ramírez
 

ALETA CNS metastasis program 8 July 2020

  • 1. A Novel Platform for Cell Therapeutics Our Journey from Bench to Clinical Development 8 July 2020 Paul D Rennert, President & CSO, Aleta Biotherapeutics
  • 2. CAR T cells work because they bind tumor antigens Cytotoxicity: This encounter triggers the CAR T cell to secrete factors that kill the tumor cells Serial killing: Each CAR T cell can find and kill up to 1000 tumor cells Proliferation: During that time the CAR T cell reproduces again and again, creating clones of itself that can carry on the anti-tumor activity Persistence: The target tumor protein must be consistently expressed at a high enough level to support CAR T cell expansion and persistence in the patient OCTS July 7-9, 20202
  • 3. When they work, cell therapies produce amazing and curative benefit in relapsed patients with no other recourse Approved anti-CD19 CAR T cell therapies for refractory B cell leukemia and lymphomas Emily Whitehead, 8 years after treatment with Kymriah, with no trace of leukemia, and still carrying her CAR T cells OCTS July 7-9, 20203
  • 4. OCTS July 7-9, 20204 CAR-T cells that target CD19 have exemplary characteristics • CAR-T cell persistence is a natural attribute of anti-CD19 CAR T cells because they can expand and persist using normal CD19+ B cells ‣ Normal B cells are a non-tumor dependent, self-renewing antigen source ‣ This antigen depot allows the CAR T cells to outlast and outlive the tumor cells • CAR-T cell fitness is naturally enhanced by the interaction with normal B cells • anti-CD19 CAR T cells are known to traffic throughout the patient, including into the central nervous system Persistence, fitness, trafficking
  • 5. Other CAR T cells just don’t work as well: why not? OCTS July 7-9, 20205
  • 6. Critical issues confront CAR T cell therapeutics for solid tumors • CAR T Cell Persistence is often poor in solid tumor indications • CAR T Cell Fitness can be limited by exhaustion and immunosuppression • CAR T Cell Trafficking may limit access to the tumor • Antigen Escape thwarts therapy due to the loss of tumor antigen expression • Patient Safety can be compromised when CAR T cells attack critical normal cells and tissues 6 OCTS July 7-9, 2020
  • 7. Our technology has two key elements designed to tackle these critical issues OCTS July 7-9, 20207 • The CAR T cell that has exemplary properties, eg. an anti-CD19 CAR T cell • Bridging Protein technology - CAR-T Engagers link CAR T cells to whatever antigen(s) we wish to target
  • 8. Bridging proteins as anti- CD19 CAR T Engagers OCTS July 7-9, 2020 8 an anti-tumor antigen domain (eg. with an scFv) with two anti-tumor antigen domains (eg. with two different llama VH) with an anti-tumor antigen VH and an anti-albumin VH • single antigen • dual antigen • half-life extended PromoterCAR192Adualepitopebridgingprotein CAR19 omoterCAR192Adualepitopebridgingprotein CAR19 CD19 VH-1 VH-2 CAR19 CD19 PromoterCAR192Adualepitopebridgingprotein CAR19CD19 CAR19 2A dual epitope bridging protein VH-1 VH-2 Vh Vl
  • 9. Delivery of bridging proteins OCTS July 7-9, 2020 9 • Biologic delivery by injection • Lentiviral delivery from a CAR T cell • Oncolytic viral delivery from a targeted tumor cell
  • 10. Bridging protein characteristics: - simple, modular, multi-antigen, adaptable OCTS July 7-9, 2020 10 Anti-CD19 CAR T cell characteristics: - persistence, fitness, trafficking
  • 11. Putting the pieces together … OCTS July 7-9, 2020 11
  • 12. Bridging proteins coat any tumor cell with CD19 • The bridging protein is the CD19 extracellular domain linked to antibody domains that bind to tumor antigens, thus coating the tumor with CD19. the antibody fragment binds a tumor antigen 12 OCTS July 7-9, 2020 PromoterCAR192Adualepitopebridgingprotein CAR19CD19 CAR19 Tumor Celltumor antigen binding CD19 CAR19 PromoterCAR192Adualepitopebridgingprotein CAR19CD19 target antigens Any tumor cell can be coated with CD19
  • 13. Bridging proteins direct anti-CD19 CAR T cells to attack any tumor cell anti-tumor protein 13 OCTS July 7-9, 2020 PromoterCAR192Adualepitopebridgingprotein CAR19CD19 CAR19 Tumor Celltumor antigen binding CD19 CAR19 PromoterCAR192Adualepitopebridgingprotein CAR19CD19 anti-CD19 CAR T cell add CAR T cells tumor cells are killedCAR T cell sees CD19
  • 14. Promoter CAR19 2A dual epitope bridging protein CAR19 CD19-anti-tumor antigen • How best to deliver the bridging protein so that it can get to the tumor? • Viral expression allows the CAR T cells to secrete the bridging protein, eg. lentiviral expression from a T cell: “all-in-one delivery” AR192Adualepitopebridgingprotein CD19 14 The bridging protein sequence is secreted by anti-CD19 CAR T cell The CAR is on the T cell surface The bridging protein is secreted from the T cell OCTS July 7-9, 2020
  • 15. The bridging protein sequence can be encoded into the CAR itself • Secreted bridging proteins (blue) coat a solid tumor cell (red) with CD19 • Now, any CAR-CD19 T cell that “sees” the CD19 will kill this solid tumor cell OCTS July 7-9, 202015 CAR-CD19 T cell CAR domain (anti-CD19) • Using a lentiviral vector, we engineer the CAR-CD19 T cell to secrete bridging proteins – this creates a Trojan Horse: the CAR T cell delivers its own CAR-T engager to attack the tumor
  • 16. Aleta-002 Treatment of Breast and Lung Cancer Patients with Her2+ CNS Metastases Stage: IND Enablement OCTS July 7-9, 202016 Clinical translation example
  • 17. The bridging protein sequence can be encoded into the CAR itself CD19-anti-Her2 BP triggers potent cytotoxicity at sub- nM concentrations OCTS July 7-9, 202017 CAR-CD19 T cell CAR domain (anti-CD19) • Aleta-002 ---- CAR-CD19 T cells that secrete a CD19-anti-Her2 bridging protein PromoterCAR192Adualepitopebridgingprotein CAR19CD19 anti-Her2
  • 18. OCTS July 7-9, 2020 Her2-bridging CAR19 T cells secreting a bridging protein cure solid tumors in vivo • CAR-CD19 T cells that secrete a CD19-anti-Her2 scFv bridging protein were injected into mice carrying Her2-positive ovarian carcinoma cells 18 DIED --- treated with control CARs, or untreated CURED --- treated with CAR-CD19 T cells that secrete the CD19-anti-Her2 scFv bridging protein
  • 19. These CARs still respond to CD19 – mice re-challenged with a CD19+ cell (Nalm6) 19 We took 4 of the survivors and re-challenged them, this time with CD19-positive Nalm6 cells; as a control we enrolled 3 naive mice: 0 5 10 15 20 0 5×107 1×108 1.5×108 2×108 2.5×108 ALT19-14 Nalm6 challenge days post Nalm6 Fluxtotal non-confidential disclosure cured mice naïve mice cured mice: no tumor growth naïve mice: lethal leukemia
  • 20. non-confidential disclosure Re-stimulation of Her2-bridging CAR-CD19 T cells 20 • Serial re-stimulation assays evaluate cytotoxicity and proliferation • Re-stimulation by a B cell line, but not a solid tumor cell line, profoundly induced robust CAR T cell proliferation • Remaining cells in each case are cytotoxic – the extent of proliferation is different • This remarkable result may further explain the poor expansion and persistence properties of CAR T cell directed to solid tumor antigens SKOV3 restimulation RAJI restimulation CAR-only CAR+SKOV3 CAR-only CAR+RAJI day 4, 1 stimulation day 8, 2 stimulations day 12, 3 stimulations day 15, 4 stimulations
  • 21. This cell therapy is uniquely and specifically designed to treat Her2-positive CNS metastases – a huge clinical need • 270,000 newly diagnosed breast cancer patients/US/year, 20% are Her2-positive • 230,000 newly diagnosed lung cancer patients/US/year, ~5% are Her2-positive  230,000 newly diagnosed colorectal cancer patients/US/year, ~4% are Her2-positive Relapsing Her2-positive cancer patients commonly have CNS metastases Relapsing patients with CNS metastases have a poor prognosis and limited therapeutic options – antibody therapy does not treat CNS disease OCTS July 7-9, 202021
  • 22. Using Her2-bridging CAR-CD19 T cells to treat CNS metastases • The CAR T cells will expand in the periphery due to the provision of CD19+ normal B cells • Activated CAR T cells will productively traffic into the CNS ‣ CNS-resident B cell leukemias and lymphomas are cleared in patients successfully treated with CAR- CD19 cellular therapy • CAR T cells that exit the CNS will encounter B cells again in the periphery 22 OCTS July 7-9, 2020
  • 23. • This is an indication where our technology provides a unique advantage – activation and persistence provided systemically (CD19-positive B cells) and locally - at the site of Her2- positive metastasis in the CNS. • Patients remain on standard of care therapy to control systemic disease = they do not have to stop trastuzumab/pertuzumab treatment. • These therapeutic profile is wholly unique and cannot be achieved by CARs directed to Her2 or by any biologic therapies. Aleta-002: Program value and differentiation OCTS July 7-9, 202023
  • 24. Aleta-003 Treatment of CNS Cancers with multi-antigen targeting CAR T therapy Stage: preclinical 24 OCTS July 7-9, 2020 Program extension
  • 25. Examples Patients Antigens Expressed Glioblastoma / astrocytoma • pediatric and adult Her2, B7H3, IL13Ra2 Medulloblastoma • rare pediatric cancer • very rare in adults Her2, B7H3, B7H6 Ependymoma • rare pediatric cancer • very rare in adults Her2, B7H3, B7H6 Meningioma • pediatric and adult Her2, B7H3, IL13Ra2 Antigen selection for refractory CNS tumors • How can we create a therapeutic to treat diverse CNS cancers? • We focused on the pattern of tumor protein expression, and then designed bispecific bridging proteins that Her2, B7H3 and other tumor antigens 25
  • 26. CAR-CD19-mediated cytotoxicity by single and dual-antigen bridging proteins 26 single dual single IC50 = 100pM = 6 ngs/ml dual IC50 = 2.5 pM = 200 pgs/ml • single antigen and dual antigen targeting of a breast cancer cell line • dual antigen targeting shifts potency dramatically • antigen expression patterns suggest safe targeting combinations • local delivery is possible (eg. AdV)
  • 27. OCTS July 7-9, 2020 Aleta’s Pipeline: diverse programs moving into development 27 Dual-Antigen
  • 28. Thank you OCTS July 7-9, 2020